Romidepsin demonstrated comparable efficacy in the 3 most common PTCL subtypes: PTCL not otherwise specified, angioimmunoblastic T-cell lymphoma, and anaplastic lymphoma kinase–negative anaplastic large cell lymphoma. The gene discussed is ALK; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.